Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

Second European PrEP Study Closed Early Due to High Effectiveness

In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomized phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. All participants assigned to receive placebo in the IPERGAY trial will be offered intermittent Truvada PrEP.

alt

Read more:

HIV Research for Prevention Conference Features Advances in Vaccines, Microbicides, PrEP

The first HIV Research for Prevention -- or HIV R4P -- conference takes place this week in Cape Town, bringing together more than 1300 leading researchers, policymakers, and advocates working on interventions such as HIV vaccines, microbicides, antiretroviral treatment as prevention (TasP), and new forms of pre-exposure prophylaxis (PrEP). The conference incorporates the previously separate HIV vaccine and microbicide meetings as biomedical prevention technologies have converged.

alt

Read more:

UCSF Announces New HIV PrEP Clinic and PrEPline Phone Consultation Service

The University of California at San Francisco has opened a new clinic to help address the unmet need for Truvada pre-exposure prophylaxis, better known as PrEP. In addition, the UCSF Clinician Consultation Center at San Francisco General Hospital has received CDC funding to operate PrEPline, a telephone consultation service to provide expert guidance to healthcare providers across the nation who wish to prescribe PrEP.

alt

Read more:

High Effectiveness Seen in English PrEP Trial, All Will Be Offered Truvada

An interim analysis of the English PROUD study data has shown that daily Truvada pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay men and other men who have sex with men (MSM) at high risk of infection. On this basis, the PROUD Trial Steering Committee has announced that participants currently on the deferred arm of the study will be offered the opportunity to begin PrEP ahead of schedule.

alt

Read more:

More iPrEx and OLE Data Published: Adherence Higher in U.S.

Participants enrolled at the U.S. study sites of the global iPrEx trial of Truvada pre-exposure prophylaxis (PrEP) achieved better adherence than those in other countries, reaching 90% in San Francisco, researchers reported in the September 16 advance edition of Journal of Acquired Immune Deficiency Syndromes. Findings from the iPrEx open-label extension (OLE) were also recently published.

alt

Read more: